DRDonna E. Reece

Donna E. Reece

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Donna E. Reece has a total of 186 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Teclistamab and daratumumab immune-based doublet therapy for relapsed/refractory multiple myeloma: the TRIMM-2 study

    by Paula Rodríguez-Otero, Daniel Morillo, Anita D’SOuza, Donna Reece, Niels W. C. J. van de Donk, Ajai Chari, Bhagirathbhai Dholaria, K. Martin Kortüm, María-Victoria Mateos, John T. McKay, et al.

    Teclistamab is the first approved B-cell maturation antigen × CD3 bispecific antibody with weight-based dosing for triple-class–exposed relapsed/refractory multiple myeloma (RRMM). We evaluated the safety and efficacy of teclistamab combined with daratumumab in the phase 1b TRIMM-2 study. Eligible patients had RRMM (≥3 previous lines of therapy [pLOT] or with disease double-refractory to a proteasome inhibitor and immunomodulatory drug); anti-CD38 exposure was permitted. Patients received subcutaneous daratumumab per approved schedule plus weight-based or fixed-dose subcutaneous teclistamab. The primary end point was safety; secondary end points included overall response rate (ORR) and duration of response (DOR). Progression-free survival (PFS) was exploratory. Sixty-one patients received weight-based, recommended phase 2 doses (RP2D; teclistamab 1.5 mg/kg weekly or 3.0 mg/kg every other week); median number of pLOTs was 5 (range, 1-14). Median follow-up was 12.0 months. Common treatment-emergent adverse events (TEAEs) included infections, cytokine release syndrome, neutropenia, and anemia; grade 3/4 TEAEs occurred in 93.4%; 7 died of TEAEs. Any-grade infections occurred in 82.0% (grade 3/4 [maximum toxicity], 45.9%; grade 5, 8.2%). No dose-limiting toxicities occurred. ORR was 68.9% (complete response or better, 44.3%); median DOR was not reached. Median PFS was 26.3 months. A cohort exploring fixed-dose teclistamab (100-300 mg) ended prematurely after a safety signal for fatal infections was identified; out of an abundance of caution, all patients were switched to weight-based dosing. In conclusion, the fully immune-based combination of weight-based RP2D teclistamab plus daratumumab demonstrated deep and durable responses, with a well-characterized safety profile. Results highlight the importance of infection management, including early immunoglobulin replacement. This trial was registered at www.clinicaltrials.gov as NCT04108195.


  • Open Access

    Supplementary Figure 3 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma

    by Rintu Sharma, Andree-Anne Pelland, Katherine Lajkosz, Esther Masih-Khan, Harjot Singh Vohra, Sita Bhella, Christine I. Chen, Vishal Kukreti, A. Keith Stewart, Suzanne Trudel, et al.

    Overall survival after teclistamab comparing a) non-Hi-MM vs Hi-MM pre-teclistamab in the training cohort, b) non-Hi-MM vs Hi-MM pre-teclistamab in the validation cohort, c) by disease burden pre-teclistamab and receipt of chemotherapy in the training cohort. The log-rank test was used to compare overall survival.

  • Open Access

    Supplementary Tables S1-S3 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma

    by Rintu Sharma, Andree-Anne Pelland, Katherine Lajkosz, Esther Masih-Khan, Harjot Singh Vohra, Sita Bhella, Christine I. Chen, Vishal Kukreti, A. Keith Stewart, Suzanne Trudel, et al.

    Supplementary Tables demonstrating correlates of overall response (Supplementary Table 1), progression-free survival (Supplementary Table 2), and overall survival (Supplementary Table 3) in the training and validation cohorts

  • Open Access

    Supplementary Figure 1 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma

    by Rintu Sharma, Andree-Anne Pelland, Katherine Lajkosz, Esther Masih-Khan, Harjot Singh Vohra, Sita Bhella, Christine I. Chen, Vishal Kukreti, A. Keith Stewart, Suzanne Trudel, et al.

    Patient disposition in the training cohort with respect to Hi-MM status at the time of debulking chemotherapy and at the time of teclistamab administration.

  • Open Access

    Data from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma

    by Rintu Sharma, Andree-Anne Pelland, Katherine Lajkosz, Esther Masih-Khan, Harjot Singh Vohra, Sita Bhella, Christine I. Chen, Vishal Kukreti, A. Keith Stewart, Suzanne Trudel, et al.

    Bispecific antibodies have revolutionized the treatment of multiple myeloma; however, primary treatment failure occurs in 30% to 40% of patients. In this study, we analyzed correlates of response to teclistamab and strategies to overcome primary resistance. Across two independent cohorts (n = 90), we developed the high risk of primary resistance (Hi-MM) variable, defined by extramedullary disease, plasma cell leukemia, bone marrow plasmacytosis ≥50%, or transfusion within 30 days, as a composite correlate of nonresponse. Patients without Hi-MM had overall response rates of 84% to 96% (vs. 20%–40% with Hi-MM) and significantly superior progression-free survival (P < 0.001) and overall survival (P < 0.001). Debulking chemotherapy was utilized in 19 patients; 79% then responded to teclistamab, including 100% who no longer had Hi-MM. All four patients who were primary refractory to a BCMA bispecific immediately prior to debulking then achieved deep responses to teclistamab. In conclusion, simple clinical parameters correlate with response to teclistamab, whereas debulking chemotherapy can overcome Hi-MM and successfully bridge patients to teclistamab or salvage nonresponders.Significance:A clinically assessable composite variable, Hi-MM, identifies patients who may benefit from debulking chemotherapy prior to teclistamab. By treating patients at a time of low disease burden or using debulking chemotherapy for those with a high risk of resistance, nearly all patients can benefit from the deep and durable remissions induced by teclistamab.

  • Open Access

    Supplementary Figure 2 from Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma

    by Rintu Sharma, Andree-Anne Pelland, Katherine Lajkosz, Esther Masih-Khan, Harjot Singh Vohra, Sita Bhella, Christine I. Chen, Vishal Kukreti, A. Keith Stewart, Suzanne Trudel, et al.

    Progression-free survival after teclistamab comparing a) non-Hi-MM vs Hi-MM pre-teclistamab in the training cohort, b) non-Hi-MM vs Hi-MM pre-teclistamab in the validation cohort, c) by disease burden pre-teclistamab and receipt of chemotherapy in the training cohort. The log-rank test was used to compare progression-free survival.

  • Open Access

    Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias

    by Sita Bhella, Gerard Agbayani, Katrina Hueniken, Abi Vijenthira, Allison M. Wilkin, Michael Sebag, Peng Wang, Lisa K. Hicks, Annette E. Hay, Seyed M. Hosseini-Moghaddam, et al.

    Plasma cell dyscrasias (PCD) are a group of hematologic disorders associated with immune dysfunction from underlying disease and/or treatment. With the continued circulation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), optimizing and maintaining durable protection in this vulnerable population through vaccination remains important. A prospective cohort study was conducted between August 2021 and January 2023 across 12 sites in Canada to evaluate humoral immunity to COVID-19 vaccination in participants with hematologic malignancies. Participants were monitored longitudinally, and finger-prick dried blood spot cards were obtained at specific intervals based on vaccination. Serum antibodies against SARS-CoV-2 proteins after the third, fourth, and fifth dose were measured by high-throughput enzyme-linked immunosorbent assay. Differences in antispike (anti-S) seropositivity by vaccine dose number and clinical risk factors were analyzed by logistic regression. A total of 262 unique participants with 983 samples were included for analysis, among which 66% were diagnosed with PCD. Analysis of the predicted probability of immunity showed consistently higher proportions of participants with PCD with vaccine (anti-S) immunity compared with those with infection-derived (antinucleocapsid) immunity throughout the study. Although vaccine responses appeared to wane 6 months after dose 3 and, to a lesser extent, after dose 4, subsequent doses cumulatively increased anti-S immunity. Seropositivity decreased with anti-CD38 therapy and older age, although the receipt of additional vaccine doses significantly improved anti-S immunity. Overall, this study demonstrated that the third and subsequent COVID-19 vaccine doses could safely improve humoral immunity in participants with PCD. Although anti-CD38 therapy and age reduced seropositivity, antibody responses could still be enhanced with vaccine doses beyond the primary 3-dose series.

  • Open Access

    Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma

    by Rintu Sharma, Andree-Anne Pelland, Katherine Lajkosz, Esther Masih-Khan, Harjot Singh. Vohra, Sita Bhella, Christine I. Chen, Vishal Kukreti, A. Keith Stewart, Suzanne Trudel, et al.

    Bispecific antibodies have revolutionized the treatment of multiple myeloma; however, primary treatment failure occurs in 30% to 40% of patients. In this study, we analyzed correlates of response to teclistamab and strategies to overcome primary resistance. Across two independent cohorts (n = 90), we developed the high risk of primary resistance (Hi-MM) variable, defined by extramedullary disease, plasma cell leukemia, bone marrow plasmacytosis ≥50%, or transfusion within 30 days, as a composite correlate of nonresponse. Patients without Hi-MM had overall response rates of 84% to 96% (vs. 20%–40% with Hi-MM) and significantly superior progression-free survival (P < 0.001) and overall survival (P < 0.001). Debulking chemotherapy was utilized in 19 patients; 79% then responded to teclistamab, including 100% who no longer had Hi-MM. All four patients who were primary refractory to a BCMA bispecific immediately prior to debulking then achieved deep responses to teclistamab. In conclusion, simple clinical parameters correlate with response to teclistamab, whereas debulking chemotherapy can overcome Hi-MM and successfully bridge patients to teclistamab or salvage nonresponders. Significance: A clinically assessable composite variable, Hi-MM, identifies patients who may benefit from debulking chemotherapy prior to teclistamab. By treating patients at a time of low disease burden or using debulking chemotherapy for those with a high risk of resistance, nearly all patients can benefit from the deep and durable remissions induced by teclistamab.


  • Open Access

    Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report

    by Martha L. Louzada, Donna Reece, Christopher P. Venner, Darrell White, Jiandong Su, Michael P. Chu, Victor H. Jimenez- Zepeda, Arleigh Mccurdy, Kevin Song, Hira Mian, et al.